Posters & Presentations

October 2026

2026 American Conference on Pharmacometrics

Population Pharmacokinetic and Pharmacodynamic Analysis of Sevasemten (EDG-5506) in Becker Muscular Dystrophy

October 2026

Heart Failure Society of America 2026 Annual Scientific Meeting

EDG-15400, An Investigational Cardiac Sarcomere Modulator, Demonstrated Favorable Pharmacokinetics, Pharmacodynamics, and Tolerability in Healthy Adult Participants

View Presentation

October 2026

Heart Failure Society of America 2026 Annual Scientific Meeting

EQUINOX-HFpEF: A Phase 2 Study of EDG-15400, a Selective Cardiac Sarcomere Modulator, in Adults with Heart Failure with Preserved Ejection Fraction

View Poster

September 2026

JCI Insight

Mechanistic Diversity Within RLC-Dependent Myosin ATPase Inhibitors Differentiates EDG-7500, a ‘Diastolic-selective’ Cardiac Sarcomere Modulator

View Publication

August 2026

ESC Congress 2026

CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy

View Presentation

July 2026

Journal of Clinical Pharmacology V66(7)

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers 

View Publication

July 2026

eBioMedicine

Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study

View Publication

May 2026

European Society of Cardiology – Heart Failure 2026

Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF

View Poster

March 2026

American College of Cardiology Scientific Session & Expo

Reduced cardiac stress and inflammatory proteomic signatures in obstructive and nonobstructive HCM following EDG-7500 treatment in CIRRUS-HCM

View Poster